Report Fraud About Us What We Do

Glumetza Antitrust Litigation Settlement For $150 Million - Lupin Pharmaceuticals' Generic Diabetes Drugs Delay

Class Action Settlements

Glumetza Antitrust Litigation Settlement For $150 Million – Lupin Pharmaceuticals’ Generic Diabetes Drugs Delay…

Lupin Pharmaceuticals To Pay $150 Million In Cash To End Antitrust Allegations Against It Regarding Generic Drug Glumetza’s Controversy

A $150 million worth settlement agreement ended the legal battle Lupin Pharmaceuticals was facing with allegations that the company was involved in a grand conspiracy in a bid to delay the release of a cheaper generic version of the diabetes medication Glumetza. 

Early reports suggest that Lupin Pharmaceuticals will be paying in cash in order to end the legal battle launched against it by customers. 

Glumetza Antitrust Litigation Settlement

Click to access In-re-Glumetza-Antitrust-Litigation.pdf

A Look At The Lupin Pharmaceuticals Glumetza Class Action Lawsuit

The class action is a compilation of different lawsuits filed against the drug maker after it allegedly worked with another pharmaceutical player, Bausch Health and Depomed (presently known as Assertio Therapeutics Inc.), to stall the release of a generic version of a diabetic drug called Glumetza. 

The complainants in the cases argued that the potentially life-saving and affordable diabetes medication variant was purposely not released at an earlier date due to the corroboration between big pharma players like Lupin Pharmaceuticals and Bausch Health and Depomed. 

They contended that Bausch Health and Depomed paid Lupin Pharmaceuticals $3 million in a deal to purposely not release the generic diabetes drug sooner. 

The said move allegedly cost countless diabetic clients hundreds of millions of money in overpaying for more expensive diabetes medication available in the market. The class action retorted that an early release could have saved consumers a large amount of money instead of opting for more expensive medicine alternatives. 

More Information

The news comes in less than just a month before the case’s official trials begin in court. Complainants in the case have already been able to undergo several legal processes like the review of pertinent and important documents in the case, Class certification briefing, and the like prior to the official trial kicking in. 

Lupin Pharmaceuticals is no stranger to antitrust legal cases. The company paid $1 million in 2020 to end a class action that accuses it of collaborating with other drugmakers to take hold and dictate the price of different birth control offerings. 

Editor’s Note on Glumetza Antitrust Litigation Settlement For $150 Million: 

This settlement article discusses the information about the developments in the antitrust litigation raised against Lupin Pharmaceuticals after it reportedly did not launch its Glumetza diabetes drug that allegedly ended up hurting consumers. You might also be interested in the Purdue Pharma Opioid Settlement for $4.5 billion.

Case Name(s) & No.(s): In re: Glumetza Antitrust Litigation; Case No.: 3:19-cv-05822

Jurisdiction: United States (U.S.) District Court for the Northern District of California 

Products/Services Involved: Generic diabetic medication Glumetza 

Allegation(s): Lupin Pharmaceuticals was involved in a monopoly to delay its Glumetza drug’s release date.

What are your thoughts on this piece? Please send us a message by clicking the ‘Contact Us’ button below! We’d love to hear back from you.

Contact Us

You can also reach out to us on Twitter or Facebook or via email at Outreach@ConsiderTheConsumer.com. Also, directly on our website! We look forward to hearing from you.

Interested in posts like these? Stay up to date with our newsletter!

No thoughts on “Glumetza Antitrust Litigation Settlement For $150 Million – Lupin Pharmaceuticals’ Generic Diabetes Drugs Delay…” yet. Be the first to speak your mind!

Leave a Reply